BrainChild Bio raises $116M
BrainChild Bio announced a Series A round of $116M on 8 September 2026. The company operates in HealthTech and is based in United States. It was founded by Steven Brugger, Chief Executive Officer. Announced 45 days ago.
Founder
Steven Brugger
Chief Executive Officer, BrainChild Bio
Outreach angles
- -Brugger is leading BrainChild Bio's push to bring Dr. Michael Jensen's foundational CAR-T research at Seattle Children's into a registration-stage clinical trial.
- -The company's therapeutic approach traces to Jensen's clinical work at Seattle Children's, now expanding into a triple-targeting CAR T therapy for glioblastoma.
- -BrainChild Bio just closed a $116 million Series A and opened its ILLUMINATE Phase 2 pivotal trial for pediatric brain cancer therapy BCB-276.
Signals
Series AHealthcareDeep TechRegulated IndustryNew Market
Round details
Company: BrainChild Bio
Domain: brainchildbio.com
Amount: $116M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 8 September 2026
Other HealthTech raises
Recently funded in United States